In an adult with rheumatoid arthritis who sustained a pathological proximal femur fracture stabilized with a proximal femoral nail, should disease‑modifying antirheumatic drug therapy be initiated post‑operatively, and if so, when?

Post-Operative DMARD Management in RA with Pathological Fracture

Yes, DMARD therapy should be initiated post-operatively after proximal femoral nail fixation, but only after confirming adequate wound healing—typically at 14 days minimum—and ruling out surgical site or systemic infection. 1

Immediate Post-Operative Period (0-14 Days)

• Withhold all DMARD therapy immediately post-operatively to allow for primary wound healing and minimize infection risk, as infection prevention takes priority over flare risk in the perioperative setting. 1

• Continue the patient's current daily glucocorticoid dose (if already receiving steroids for RA) rather than administering stress-dose steroids; optimization should aim for <20 mg/day prednisone-equivalent when possible. 1

• Monitor the surgical wound closely for signs of healing: absence of significant swelling, erythema, or drainage, and removal of all sutures/staples. 1

• Screen for non-surgical site infections (respiratory, urinary, systemic) before restarting any immunosuppressive therapy. 1

DMARD Restart Criteria (≥14 Days Post-Op)

Restart biologic DMARDs and conventional synthetic DMARDs when ALL of the following criteria are met: 1

• Wound shows evidence of healing (typically ~14 days minimum)
• All sutures/staples have been removed
• No significant swelling, erythema, or drainage at the surgical site
• No clinical evidence of surgical site infection
• No active non-surgical site infections

Treatment Algorithm for DMARD-Naïve Patients

If Patient Was NOT on DMARDs Pre-Operatively:

Initiate methotrexate 15-25 mg weekly with folic acid supplementation immediately once wound healing criteria are met, rapidly escalating to 25-30 mg weekly within a few weeks. 1, 2

• Add low-dose prednisone ≤10 mg/day as a short-term bridge (<3 months) for rapid symptom control while methotrexate takes effect. 2, 3

• Assess disease activity every 1-3 months using validated measures (SDAI, CDAI, or DAS28); aim for remission (SDAI ≤3.3, CDAI ≤2.8) or low disease activity (SDAI ≤11, CDAI ≤10). 1, 2, 3

• If inadequate response at 3 months or target not reached by 6 months, escalate to combination therapy:

  • Add hydroxychloroquine 400 mg daily + sulfasalazine (titrate to 1000 mg twice daily) for triple-DMARD therapy 2, 3
  • OR add a biologic DMARD (TNF inhibitor preferred) if poor prognostic factors present (high RF/anti-CCP, erosive disease, high disease activity) 1, 2, 3

If Patient Was on DMARDs Pre-Operatively:

Resume the previous DMARD regimen (methotrexate, biologics, or combination therapy) once wound healing criteria are met at 14+ days. 1

• Restart biologic agents based on wound status and clinical judgment for absence of infection, not on arbitrary timelines beyond the 14-day minimum. 1

• For biologics with different dosing intervals, timing examples include: 1

  • Adalimumab (every 2 weeks): restart at week 3 post-op
  • Infliximab (every 8 weeks): restart at week 9 post-op
  • Rituximab (every 6 months): restart at month 7 post-op

Critical Pitfalls to Avoid

• Do NOT delay DMARD initiation beyond wound healing in DMARD-naïve patients, as this permits irreversible joint damage and disease progression. 1, 2

• Do NOT restart DMARDs before 14 days or while active infection is present, as infection risk outweighs flare risk in the immediate post-operative period. 1

• Do NOT use NSAIDs or corticosteroids as sole therapy for RA management; they provide only symptomatic relief without disease modification. 1, 2

• Do NOT continue systemic corticosteroids beyond 1-2 years due to cumulative toxicity (fractures, cataracts, cardiovascular disease, osteoporosis). 1, 2

• Do NOT use hydroxychloroquine monotherapy as first-line treatment; it has weak disease-modifying effects and no proven structural benefit in moderate-to-high disease activity. 2, 4

Special Considerations for Pathological Fractures

• Pathological fractures in RA indicate aggressive disease requiring intensive DMARD therapy once medically appropriate; these patients typically have poor prognostic factors warranting early combination or biologic therapy. 2, 3

• Optimize bone health with calcium 500-1000 mg daily and vitamin D 800-1000 IU daily, especially if prolonged corticosteroid use; consider bisphosphonate if DEXA shows osteoporosis. 2

• Ensure adequate fracture healing before weight-bearing and aggressive physical therapy; coordinate with orthopedic surgery regarding rehabilitation timeline. 1